Compare CF Industries Holdings, Inc. (CF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CF Industries Holdings, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? CF Industries Holdings, Inc. trades at $120 (market cap $17.83B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: CF Industries Holdings, Inc. pays a 2.04% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, CF Industries Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CF | XBI | |
|---|---|---|
Market Cap | $17.83B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $137.55 | $164.28 |
52-Week Low | $76.08 | $86.92 |
Enterprise Value | $18.96B | — |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CF Industries trades at $119.33, down 1.8% with bearish technical signals. The stock shows strong fundamentals with a P/E of 8.74 and ROE of 39.19%, though Q2 2026 earnings missed expectations. Revenue grew to $7.08B in 2025 with net income of $1.46B. Analyst consensus remains positive with 51% buy ratings and a $119.60 price target. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced holdings.
The outlook remains cautiously optimistic given strong nitrogen market fundamentals and improving cash flow trends. Key risks include production volatility and commodity price sensitivity. With current pricing near analyst targets, the stock offers value but requires monitoring of operational execution and global fertilizer demand trends.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
